Clinical Efficacy of Entecavir Combined with Adefovir Dipivoxil in Lamivudine-resistant Chronic Hepatitis

CHEN Yu

doi:10.14033/j.cnki.cfmr.2015.16.001

Abstract：Objective:To investigate the clinical efficacy of Entecavir(ETV) combined with Adefovir Dipivoxil(ADV) in lamivudine-resistant chronic hepatitis B(CHB) patients.Method:56 cases of CHB patients from January 2012 to December 2013 in our hospital were randomly divided into the treatment group and the control group,28 cases in each group.The HBV-DNA,ALT,AST,TBil,Alb and HBV serological markers(HBV M),HBeAg seroconversion rates and other indicators of adverse events were compared before and after treatment the first week 4,12,24,48 plasma.Result:After treatment,ALT and AST four time points compared with the control group were significantly decreased(P<0.05).TBil 12 weeks after treatment was significantly decreased(P<0.05). Alb after 4 weeks of treatment was significantly higher(P<0.05),the rest of the observation points,compared with the control group,there were no significant differences(P>0.05).The treatment group of four time points HBV DNA negative rate was significantly higher(P<0.05).The treatment group and the control group of four time points in patients with HBeAg positive negative rate difference were no statistically significant(P>0.05).48 weeks after the treatment group was 0 resistance gene mutation was significantly lower than 17.6%in the control group.The incidence of adverse reactions compared two groups,there was no statistically significant difference(P>0.05).Conclusion:The ETV combined with ADV in lamivudine-resistant CHB patients has a lamivudine-resistant exact,lower incidence of multi-drug resistance and side effects,which is worthy of promotion.